-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $21

Benzinga·05/06/2026 18:30:48
Listen to the news
TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises the price target from $19 to $21.